EGFR Immunotherapy available

BARC is now offering a unique immunotherapy that targets the EGFR/HER2 pathway. Epidermal Growth Factor Receptor (EGFR) is overexpressed on a number of human cancers, and often is indicative of a poor outcome.

We are hoping to induce a polyclonal anti-EGFR/HER2 tumor antigen response by vaccine therapy.

We are enrolling companion dogs with spontaneous EGFR expressing tumors to receive a series of 2 vaccines 3 weeks apart. There is annother visit after vaccination to draw a blood sample for antigen response analysis. Dogs with EGFR expressing tumors will be immunized with a short peptide of the EGFR extracellular domain with sequence homology to HER2.

To receive the immunotherapy without required Oncologist consultation:

1. Referral direct from another Veterinary Oncologist

2. Viable tumor types include:

• Osteosarcoma patients

• Hemangiosarcoma patients

• Transitional Cell Carcinoma

• Pulmonary Carcinoma (with records review)

• High grade Mast cell tumors (with records review)

Naive patients can also schedule to have an Oncology consult and this therapy will be discussed if applicable to your dogs disease profile.

Please contact us today for more information!